Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1 |
| |
Authors: | Hanki Lee Joo-Won Suh |
| |
Affiliation: | 1.Center for Nutraceutical and Pharmaceutical Materials,Myongji University,Yongin,South Korea;2.Division of Biosciences and Bioinformatics, College of Natural Science,Myongji University,Yongin,South Korea |
| |
Abstract: | Tuberculosis (TB) is a serious and potentially fatal disease caused by Mycobacterium tuberculosis (M. tb). The occurrence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tb is a significant public health concern because most of the anti-TB drugs that have been in use for over 40 years are no longer effective for the treatment of these infections. Recently, new anti-TB lead compounds such as cyclomarin A, lassomycin, and ecumicin, which are cyclic peptides from actinomycetes, have shown potent anti-TB activity against MDR and XDR M. tb as well as drug-susceptible M. tb in vitro. The target molecule of these antibiotics is ClpC1, a protein that is essential for the growth of M. tb. In this review, we introduce the three anti-TB lead compounds as potential anti-TB therapeutic agents targeting ClpC1 and compare them with the existing anti-TB drugs approved by the US Food and Drug Administration. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|